Seattle Genetics has completed the acquisition of Cascadian Therapeutics for $614m.
Based in Switzerland, Seattle Genetics is a biotechnology company, while Cascadian Therapeutics is a US-based biopharmaceutical company.
The target company is currently developing the oral tyrosine kinase inhibitor Tucatinib for the treatment of HER2 growth factor receptor overexpressed cancers.
Tucatinib is being investigated in a pivotal trial called HER2CLIMB. The drug has already demonstrated a favourable tolerability and efficacy profile in phase Ib trials.
The acquisition will strengthen Seattle Genetics’ late-stage cancer drug pipeline and establish it as a multi-product oncology company.
Gryphon Investors has acquired Matrixx Initiatives from a division of H.I.G. Capital.
Based in the US, Gryphon Investors is a private equity firm, while Matrixx Initiatives, also based in the US, is an over-the-counter (OTC) healthcare company.
India-based private equity firm ChrysCapital has acquired a minority stake in Curatio Healthcare Pvt. Ltd for Rs1.3bn ($20m).
Based in India, the target company is a manufacturer of skincare products.
The managing director of Curatio, G.K. Ramani, and Fulcrum Venture India hold 67% of the share in the company, while the remaining share is held by Sequoia Capital.
Ramani has diluted his stake in the company and Fulcrum has made a partial exit.